ARTICLE | Company News
Implicit Biosciences, Eli Lilly deal
March 2, 2009 8:00 AM UTC
Implicit acquired exclusive, worldwide rights to Eli Lilly's IC14 for an undisclosed sum, including cash and stock. Implicit expects to begin Phase II testing of the antibody against CD14 to treat a...